We describe the development, characterization, and preclinical validation of 22.0405.aF, a potential first-in-class afucosylated anti-ROR1 antibody, which recently completed Phase 0 clinical investigation (NCT06273852) in patients with head and neck carcinomas and soft tissue sarcomas. This evidence concerns the gene ROR1 and soft tissue sarcoma.